Kinetic Capital Partners

CXIP Labs is a developer of NFT infrastructure solutions for the web3 ecosystem.

BlockApps is making digital ownership real through the development of the STRATO Mercata Blockchain Protocol and Marketplace. With a network of verified partners, whiskey casks, precious metals, carbon offsets and collectibles are available for anyone to purchase. Born from the launch of Ethereum, BlockApps has worked with some of the world’s largest enterprises and governments and has raised approximately $50 million in investment. BlockApps was founded in 2015 and is headquartered in Brooklyn, New York.

World connects users through a privacy-focused network with secure digital asset management. The company is a privacy-focused human network incorporating a financial system to enhance global connectivity and trust. The World App allows users to securely store a World ID, manage digital assets, and easily access various Mini Apps.

Dtravel is a decentralized platform for the home-sharing economy facilitating short and long-term stays payable with cryptocurrency and traditional payment methods.

Flare is a powerful new blockchain with the first consensus protocol for external data. Decentralized applications on Flare can therefore trustlessly acquire and use information from other blockchains and real world data sources, solving the oracle problem and opening the door to a new era of utility. > Fast, decentralized and fully-insured bridges can connect smart contract chains multilaterally, unifying rather than fragmenting liquidity. > Non-smart contract assets such as BTC, XRP and DOGE can be brought on to Flare, and put to work earning yield in DeFi. > Full cross-chain composability enables decentralized applications to use the value, liquidity and information of multiple blockchains via a single deployment on Flare. > Seamless decentralized integration with Web2 data powers trustless use of real world data sources in Web3 dapps.

SubDAO Network is a DAO management platform that aims to provide a chain of tools to facilitate DAO’s creation. SubDAO is a DAO infrastructure based on Polkadot, where any decentralized organization is allowed to conveniently create and manage a DAO. SubDAO does not only connect DAO with DApps to realize DAO’s cross-chain management, but also bridges Web 2.0 and Web 3.0.

Convergence Finance is a decentralized interchangeable asset protocol.

Terra is a price-stable cryptocurrency designed for mass adoption. It builds financial infrastructure for the next generation of decentralized applications. Terra is backed by Luna, a decentralized asset that derives its value from transaction fees collected on the Terra network. Much like the moon stabilizes the earth’s rotation, Luna is Terra's eternal guardian of stability.

Cere Network is a blockchain CRM ecosystem platform optimized for service data integration and collaboration. The Cere Blockchain solutions capture the entire customer journey on the blockchain and stores key user data such as purchases, achievements, and usage in the user wallet.

Opium Team operates a blockchain-based financial platform that focuses on the creation, settlement, and trading of derivatives. Founded in 2018 and based in Rotterdam, the Netherlands, the company provides a decentralized protocol for various financial applications, including trade settlement and risk management. Users can create derivatives, utilize oracles for asset pricing, and manage portfolios within this ecosystem. The platform also features smart contracts, a crypto wallet, and an API, facilitating a transparent and audited framework for trading products like ETH futures, gas options, and synthetic pre-markets for decentralized finance (DeFi) tokens. By leveraging innovative technology, Opium Team aims to disrupt traditional financial services with its comprehensive range of offerings.

Linear Finance is a cross-chain compatible, decentralized delta-one asset protocol to cost-effectively and instantly create, manage, and trade synthetic assets with unlimited liquidity.

Reef Finance is a DeFi platform that enables trading with access to liquidity from both CEXes and DEXes while offering smart lending, borrowing, staking, mining through an AI-driven personalized Reef Yield Engine. Reef Finance is the first Polkadot project ever launched on Binance Launchpool. Reef Finance was established in 2019 by CEO and founder Denko Mancheski.

ThunderCore is a secure, high-performance, EVM-compatible public blockchain with its own native currency, TT. With a breakthrough consensus protocol that overcomes the scalability “trilemma” called PaLa, the ThunderCore network offers 4,000+ TPS, 1 second confirmation times, and low gas fees that cost less than a fraction of a cent, giving decentralized applications security and scalability. Currently, ThunderCore has an international user base that spans across more than 190 countries.

Eximchain enables businesses to connect, transact, and share information more efficiently and securely through our blockchain utility infrastructure. Using Eximchain blockchain technology, enterprises can eliminate traditional supply chain barriers and integrates actors big and small into an efficient, transparent, and secure global network.

Bluzelle offers a complete and fully integrated stack of blockchain applications, middleware and data services. With customers that range from SMEs to global enterprises, Bluzelle is able to design, develop and deploy the best solution for your business.

Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Particle technology, an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. The company also develops Hepatitis siRNA products for the treatment of hepatitis B and C. Protiva Biotherapeutics, Inc. has a research and development facility in Vancouver, Canada. The company was founded in 2000 and is based in Seattle, Washington. As of May 30, 2008, Protiva Biotherapeutics, Inc. operates as a subsidiary of Tekmira Pharmaceuticals Corp.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

AgInfoLink Inc. designs and develops traceability solutions for the food industry. It offers data collection, secure data transmission, data warehousing, reporting, and analysis tools for linking information for individual animal management, regulatory compliance, and business performance. The company provides Pony Express, a data sharing solution to create and customize a data sharing network for supply chain; BeefLink, a personal computer-based data collection and management system to capture and store data automatically from RFID and barcode tags, scales, and other devices; AgInfoReports and AgInfoSheets reporting systems; and AgMobile, a handheld unit and wireless RFID reader that allows livestock producers to identify animals, record data, and reference historical data. AgInfoLink, Inc. also offers CattleCard, a data collection solution, for customers without computers, to collect group data and individual data using a barcode label sticker and RFID identifier; Tag Tracker, a rugged hand-held wireless RFID reader reads an RFID tag and communicates with a base station; and Animal Logger, a solution for collecting NAIS required and basic animal movement information, as well as WebReporting and Decision Pro tools, and processed verification programs. It serves state regulators, meat processors, retail/foodservice, and livestock producers. The company was founded in 1997 and is based in Longmont, Colorado.

Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Particle technology, an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. The company also develops Hepatitis siRNA products for the treatment of hepatitis B and C. Protiva Biotherapeutics, Inc. has a research and development facility in Vancouver, Canada. The company was founded in 2000 and is based in Seattle, Washington. As of May 30, 2008, Protiva Biotherapeutics, Inc. operates as a subsidiary of Tekmira Pharmaceuticals Corp.